Ingenol Mebutate
FDA-approved product (gel, topical), marketed as Ingenol Mebutate, Picato.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Actinic keratosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other chemotherapeutics
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX02
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ingenol Mebutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
NCT01302925 · start 2011-02
Registered record
- Registry ID
- NCT01302925
- Conditions
- Healthy; Actinic Keratosis
- Interventions
- PEP005 Gel; PEP005 Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2011-03
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy; Actinic KeratosisInterventionPEP005 Gel; PEP005 GelPhasePhase 1Registry statusCompletedStudy to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
NCT01214577 · start 2010-10
Registered record
- Registry ID
- NCT01214577
- Conditions
- Photo-damage
- Interventions
- PEP005 (ingenol mebutate) Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2011-01
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPhoto-damageInterventionPEP005 (ingenol mebutate) GelPhasePhase 2Registry statusCompletedA Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
NCT00989313 · start 2009-09
Registered record
- Registry ID
- NCT00989313
- Conditions
- Actinic Keratosis
- Interventions
- Lesion count
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2010-10
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionLesion countPhaseNot recordedRegistry statusCompletedA Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
NCT00953732 · start 2009-08
Registered record
- Registry ID
- NCT00953732
- Conditions
- Actinic Keratosis
- Interventions
- Lesion count
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-08
- Completion
- 2010-10
- Enrolment
- 117
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionLesion countPhaseNot recordedRegistry statusCompletedA Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
NCT00917306 · start 2009-06
Registered record
- Registry ID
- NCT00917306
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-06
- Completion
- 2009-09
- Enrolment
- 102
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 GelPhasePhase 3Registry statusCompletedA Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
NCT00852137 · start 2009-03
Registered record
- Registry ID
- NCT00852137
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 (ingenol mebutate) Gel, 0.05%; Vehicle Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2009-06
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 (ingenol mebutate) Gel, 0.05%; Vehicle GelPhasePhase 2Registry statusCompletedA Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
NCT00850681 · start 2009-02
Registered record
- Registry ID
- NCT00850681
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 (ingenol mebutate) Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2009-04
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 (ingenol mebutate) GelPhasePhase 1Registry statusCompletedA Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
NCT00850811 · start 2009-02
Registered record
- Registry ID
- NCT00850811
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 (ingenol mebutate) Gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2009-04
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 (ingenol mebutate) GelPhasePhase 1Registry statusCompletedA Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
NCT00742391 · start 2008-09
Registered record
- Registry ID
- NCT00742391
- Conditions
- Actinic Keratoses
- Interventions
- PEP005 (ingenol mebutate) Gel; Vehicle gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2009-02
- Enrolment
- 255
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosesInterventionPEP005 (ingenol mebutate) Gel; Vehicle gelPhasePhase 3Registry statusCompletedA Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
NCT00700063 · start 2008-06
Registered record
- Registry ID
- NCT00700063
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 Topical Gel; PEP005 Topical Gel; PEP005 Topical Gel; Vehicle gel; PEP005 Topical Gel; PEP005 Topical Gel; PEP005 Topical Gel; Vehicle gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2008-10
- Enrolment
- 265
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 Topical Gel; PEP005 Topical Gel; PEP005 Topical Gel; Vehicle gel +4 morePhasePhase 2Registry statusCompletedA Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
NCT00544297 · start 2007-10
Registered record
- Registry ID
- NCT00544297
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2008-01
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 gelPhasePhase 2Registry statusCompletedThe Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
NCT00546611 · start 2007-10
Registered record
- Registry ID
- NCT00546611
- Conditions
- Warts
- Interventions
- PEP005
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2007-10
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWartsInterventionPEP005PhasePhase 1Registry statusWithdrawnTo Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
NCT00432185 · start 2007-02
Registered record
- Registry ID
- NCT00432185
- Conditions
- Superficial Basal Cell Carcinoma
- Interventions
- PEP005
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-02
- Completion
- 2010-03
- Enrolment
- 117
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSuperficial Basal Cell CarcinomaInterventionPEP005PhasePhase 2Registry statusCompletedA Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
NCT00427050 · start 2007-01
Registered record
- Registry ID
- NCT00427050
- Conditions
- Actinic Keratoses
- Interventions
- PEP005
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2007-11
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosesInterventionPEP005PhasePhase 2Registry statusCompletedStudy to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design
NCT00357916 · start 2006-06
Registered record
- Registry ID
- NCT00357916
- Conditions
- Healthy
- Interventions
- PEP005 Topical Gel (0.01% concentration)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2006-10
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionPEP005 Topical Gel (0.01% concentration)PhasePhase 1Registry statusCompleted